Glucocorticoid Receptor
Glucocorticoid Receptor research on this page centres on nuclear receptor coactivator 2 (NCOA2), also known as SRC-2, TIF2, GRIP1 and NCoA-2. It is a nuclear transcriptional coactivator for steroid and other nuclear receptors, and it supports glucocorticoid receptor activity. Browse Assay Genie's current range of Glucocorticoid Receptor research reagents below, or read on for the biology behind the target.
NCOA2 is a transcriptional coactivator for steroid receptors and other nuclear receptors. It acts as an intermediary factor for the ligand-dependent activity of these receptors, which regulate their target genes after binding cognate response elements. It coactivates through the steroid-binding domain (AF-2) but not the modulating N-terminal domain (AF-1). The NCBI Gene summary lists steroid, thyroid, retinoid and vitamin D receptors among its partners.
In the context of glucocorticoid signalling, the sumoylation enhancer RWDD3 positively regulates the transcriptional activity of the glucocorticoid receptor NR3C1, and NCOA2 is involved in this regulation. Beyond this, NCOA2 is required with NCOA1 to control energy balance between white and brown adipose tissues. It is a critical regulator of glucose metabolism, acting as a RORA coactivator to modulate G6PC1 expression. It also positively regulates the circadian clock as a coactivator for the CLOCK-BMAL1 heterodimer.
The NCOA2 gene encodes a nuclear protein of the SRC/p160 nuclear receptor coactivator family. HGNC places it among the basic helix-loop-helix proteins, the lysine acetyltransferases (as KAT13C) and PAS domain containing proteins, and it also carries the symbol bHLHe75. Alternative splicing produces multiple transcript variants. The gene is involved in translocations that create fusions with KAT6A in acute myeloid leukaemia, ETV6 in acute lymphoblastic leukaemia and HEY1 in mesenchymal chondrosarcoma. Mouse and rat each have an Ncoa2 ortholog.
NCOA2 is involved in the positive regulation of glucocorticoid receptor NR3C1 transcriptional activity by the sumoylation enhancer RWDD3.
NCOA2 acts as an intermediary factor for ligand-dependent steroid, thyroid, retinoid and vitamin D receptor activity at response elements.
NCOA2 works with NCOA1 to control energy balance between white and brown adipose tissues and regulates glucose metabolism via RORA and G6PC1.
NCOA2 coactivates CLOCK-BMAL1 and forms gene fusions with KAT6A, ETV6 and HEY1 in leukaemias and chondrosarcoma.
NCOA2 is a transcriptional coactivator for steroid and other nuclear receptors, acting through the AF-2 domain. It helps control adipose energy balance with NCOA1, regulates glucose metabolism as a RORA coactivator, and coactivates CLOCK-BMAL1 in the circadian clock.
No. The glucocorticoid receptor is NR3C1. NCOA2, also called SRC-2, TIF2 or GRIP1, is a coactivator, and RWDD3 positively regulates NR3C1 transcriptional activity in a process involving NCOA2. Other names include NCoA-2, KAT13C and bHLHe75.
NCOA2 fusions with KAT6A, ETV6 and HEY1 occur in acute myeloid leukaemia, acute lymphoblastic leukaemia and mesenchymal chondrosarcoma respectively. Mouse and rat have an Ncoa2 ortholog; check the datasheet of any product for its validated reactivity.
Other nuclear receptor coactivators, glucocorticoid signalling partners and fusion-gene partners with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q15596; product specifications from Assay Genie datasheets.